Tenaya Therapeutics (TNYA) Liabilities and Shareholders Equity (2020 - 2026)

Tenaya Therapeutics' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $135.1 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 6.17% year-over-year to $135.1 million in Q1 2026; TTM through Mar 2026 was $509.1 million, a 10.31% decrease from a year earlier, with the FY2025 full-year figure at $146.9 million, up 22.5% from the prior year.
• Liabilities and Shareholders Equity eased to $135.1 million in Q1 2026 per TNYA's latest filing, from $146.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $281.5 million in Q1 2022 and bottomed at $105.0 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $170.5 million (2023), against an average of $184.4 million.
• Across the five-year window, Liabilities and Shareholders Equity jumped 63.12% in 2022 and plunged 38.87% in 2023, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $278.9 million in 2022, then tumbled by 38.87% to $170.5 million in 2023, then decreased by 29.66% to $119.9 million in 2024, then rose by 22.5% to $146.9 million in 2025, then retreated by 8.07% to $135.1 million in 2026.
• Per Business Quant, the three latest TNYA Liabilities and Shareholders Equity figures stand at $135.1 million (Q1 2026), $146.9 million (Q4 2025), and $105.0 million (Q3 2025).